These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 36164841)
1. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab. Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841 [No Abstract] [Full Text] [Related]
2. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis. Karstarli Bakay OS; Kacar N Dermatol Ther; 2022 Sep; 35(9):e15638. PubMed ID: 35703106 [No Abstract] [Full Text] [Related]
3. Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series. Bonnekoh H; Kiefer L; Buttgereit T; Kolkhir P; Lütke-Eversloh M; Scheffel J; Maurer M; Metz M J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2578-2580.e1. PubMed ID: 37244440 [No Abstract] [Full Text] [Related]
4. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria. Skander D; Allenova A; Maurer M; Kolkhir P Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030 [No Abstract] [Full Text] [Related]
5. Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis. Holm JG; Sørensen JA; Thomsen SF Int J Dermatol; 2022 May; 61(5):e173-e174. PubMed ID: 34813086 [No Abstract] [Full Text] [Related]
6. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders? Asero R Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398 [No Abstract] [Full Text] [Related]
12. Validation of UAS7 among children with chronic spontaneous urticaria. Gabrielli S; Mulé P; Prosty C; Gooding G; Le M; Zhang L; Netchiporouk E; Baum S; Greenberger S; Ensina LF; Lovett A; Zhang X; Ben-Shoshan M J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1927-1929.e1. PubMed ID: 35272072 [No Abstract] [Full Text] [Related]
13. Ligelizumab for the treatment of chronic spontaneous urticaria. Wedi B Expert Opin Biol Ther; 2020 Aug; 20(8):853-861. PubMed ID: 32380864 [TBL] [Abstract][Full Text] [Related]
17. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):T88-T90. PubMed ID: 37871896 [No Abstract] [Full Text] [Related]
18. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):88-90. PubMed ID: 36754254 [No Abstract] [Full Text] [Related]
19. Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria. Moussa S; Netchiporouk E Lancet; 2024 Jan; 403(10422):118-119. PubMed ID: 38008108 [No Abstract] [Full Text] [Related]
20. Efficacy of additional treatment for chronic spontaneous urticaria refractory to treatment - A single-center retrospective real-world study. Ohata M; Oda Y; Washio K; Fukunaga A; Nishigori C J Dermatol; 2022 Jan; 49(1):e7-e8. PubMed ID: 34632611 [No Abstract] [Full Text] [Related] [Next] [New Search]